Status:

COMPLETED

Aripiprazole in Children With Autism: A Pilot Study

Lead Sponsor:

Drexel University College of Medicine

Conditions:

Autism

Eligibility:

All Genders

12-18 years

Phase:

PHASE2

Brief Summary

This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism. Children who qualify for the study will be treated with aripiprazole fo...

Detailed Description

I. SPECIFIC AIM To obtain pilot data regarding the safety, dosing, and efficacy of open-labeled aripiprazole in children, aged 12 to 18 years, diagnosed with autism. A larger, more controlled trial w...

Eligibility Criteria

Inclusion

  • Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.
  • Males and females.
  • Aged 12 to 18 years.
  • Clinical judgment that medication treatment for autism is indicated.

Exclusion

  • Major medical problems including cardiac, liver, endocrine, or renal diseases.
  • Uncontrolled seizures.
  • Baseline QTC greater than 425 msec.
  • Concomitant treatment with psychotropic medication.
  • History of prior exposure to aripiprazole.

Key Trial Info

Start Date :

February 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 16 2011

Estimated Enrollment :

11 Patients enrolled

Trial Details

Trial ID

NCT00208533

Start Date

February 1 2004

End Date

November 16 2011

Last Update

July 30 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Drexel University College of Medicine at Friends Hospital

Philadelphia, Pennsylvania, United States, 19124